Complementary role of vitamin D deficiency and the interleukin‐28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C

@article{Bitetto2011ComplementaryRO,
  title={Complementary role of vitamin D deficiency and the interleukin‐28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C},
  author={Davide Bitetto and Giovanna Fattovich and Carlo Fabris and Elisa Ceriani and Edmondo Falleti and Ezio Fornasiere and Michela Pasino and Donatella Ieluzzi and Annarosa Cussigh and Sara Cmet and Mario Pirisi and Pierluigi Toniutto},
  journal={Hepatology},
  year={2011},
  volume={53}
}
The widely accepted interleukin‐28B (IL‐28B) rs12979860 C/T polymorphism and the more recently proposed vitamin D serum concentration are two novel predictors of the response to antiviral treatment in chronic hepatitis C virus (HCV) infection. This study aimed to verify whether the IL‐28B rs12979860 C/T polymorphism and pretreatment serum vitamin D levels have independent or complementary roles in predicting the rates of sustained viral response (SVR). The present study included 211 consecutive… 
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C
TLDR
In difficult‐to‐treat HCV genotypes, simultaneous pretreatment normal serum vitamin D levels and the carriage of GC‐globulin WT isoform strongly predicts the achievement of SVR after PEG‐interferon plus ribavirin antiviral therapy.
Vitamin D and IL 28 B Genotyping as Predictors for Antiviral Therapy : A Retrospective Study in Egyptian HCV Genotype 4 a
TLDR
Evaluating the role of pre-treatment vitamin D serum level and interleukin28B (IL28B) polymorphism in chronic hepatitis C (CHC) genotype 4a patients treated with pegylated interferon α2-A and ribavirin as predictors of response found them to be independent trait predictor of SVR.
Vitamin D and IL28B Genotyping as Predictors for Antiviral Therapy: A Retrospective Study in Egyptian HCV Genotype 4a
TLDR
Evaluating the role of pre-treatment vitamin D serum level and interleukin28B (IL28B) polymorphism in chronic hepatitis C (CHC) genotype 4a patients treated with pegylated interferon α2-A and ribavirin as predictors of response found them to be independent trait predictor of SVR.
Vitamin D‐related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C
TLDR
The IL28B polymorphism and serum 25(OH) D3 level contributed significantly and independently to SVR in PR combined with PI for genotype 1b‐infected chronic hepatitis C patients, however, none of vitamin D‐related gene polymorphisms had an impact on the treatment outcome and serum25(OH] D3level.
Role of vitamin D in chronic hepatitis C
  • Tae Yeob Kim
  • Biology, Medicine
    The Korean Journal of Hepatology
  • 2011
TLDR
The best predictor of long-term response for chronic hepatitis C (CHC) to treatment is sustained virological response (SVR), defined as undetectable serum HCV RNA by PCR assay at 24 weeks after cessation of therapy.
Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial
TLDR
Although patients with the TG/GG genotype, who were relatively resistant to PEG‐IFN treatment, had similar VR rates at week 24 with and without vitamin D supplementation, the decline in viral load from week 8 to week 24 was significantly greater with than withoutitamin D supplementation.
Influence of Vitamin D-Related Gene Polymorphisms (CYP27B and VDR) on the Response to Interferon/Ribavirin Therapy in Chronic Hepatitis C
TLDR
VDR gene polymorphisms are independently related to the response to Peg-IFN+RBV therapy in chronic hepatitis C and could be used as complementary biomarkers of response when included in a prediction algorithm in association with demographic, virologic, biochemical and genetic traits.
Vitamin D Receptor FokI Gene Polymorphism Predicted Poor Response to Treatment in Chronic HCV Genotype 4
TLDR
VDR polymorphism plays a role in the treatment response of HCV and the modification of disease progression in Egyptians infected with chronic HCV-4.
Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon‐based antiviral therapy
TLDR
A high percentage of patients with chronic HCV infection have serum vitamin A deficiency, and this condition is associated with nonresponse to antiviral therapy.
Genetic Polymorphisms of Vitamin D Pathway Predict Antiviral Treatment Outcome in Slow Responder Naïve Patients with Chronic Hepatitis C
TLDR
Observations could permit to extend the indication to adopt dual antiviral therapy beyond RVR positivity rule without reducing the chances of SVR.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon‐based therapy in genotype 1 chronic hepatitis C
TLDR
Low vitamin D is linked to severe fibrosis and low SVR on interferon (IFN)‐based therapy and G1 CHC patients had low 25(OH)D serum levels, possibly because of reduced CYP27A1 expression.
Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C
  • D. Bitetto, C. Fabris, P. Toniutto
  • Medicine
    Transplant international : official journal of the European Society for Organ Transplantation
  • 2011
TLDR
In conclusion, vitamin D deficiency predicts an unfavourable response to antiviral treatment of RHC and vitamin D supplementation improves the probability of achieving a SVR following antiviral therapy.
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
TLDR
In treatment-naive HCV-1 patients treated with pegylated interferon and ribavirin, a polymorphism upstream of IL-28B is associated with increased on-treatment and sustained virologic response and effectively predicts treatment outcome.
Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.
  • A. Stättermayer, R. Stauber, P. Ferenci
  • Medicine, Biology
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2011
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.
TLDR
The rs12979860 genotype is a significant independent predictor of response to PEG-IFN/RBV in patients with chronic HCV infection; tests for this genotype might be used to determine the best course of treatment for patients considering antiviral therapy.
Associations between serum lipids and hepatitis C antiviral treatment efficacy
TLDR
Serum lipids are associated with SVR, although these paramaters did not explain the racial difference in treatment response, and the results are compatible with proposed biological mechanisms of HCV entry, replication, and secretion and may underscore new potential therapeutic targets for HCV eradication.
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
TLDR
The goal of this review is to present the mechanisms of non‐response, to overcome it and to identify factors that can help to predict the response to anti‐HCV therapy.
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
TLDR
It is reported that a genetic polymorphism near the IL28B gene, encoding interferon-λ-3 (IFN-α-2a) is associated with an approximately twofold change in response to treatment, both among patients of European ancestry and African-Americans.
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
TLDR
Insulin resistance, fibrosis, and genotype are independent predictors of the response to antiviral therapy in chronic hepatitis C patients treated with peginterferon plus ribavirin.
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy
TLDR
Baseline elevated LDL levels or low HDL levels and preemptive statin usage were associated with higher SVR rates, and Prospective studies may be considered to explore the biological impact of these factors on HCV RNA replication and treatment response.
...
1
2
3
4
...